Background
Methods
Disease selection
National disease expert surveys
Pathogen | Disease and case definition |
---|---|
Extra-intestinal pathogenic Escherichia coli (ExPEC) | Invasive ExPEC disease: laboratory-confirmed sepsis-causing ExPEC, based on invasive isolates from blood or cerebrospinal fluid |
Norovirus (NoV) | 1. Norovirus infection: diarrhoea or vomiting or both in a 24-h period confirmed by a positive laboratory test (nucleic acid amplification assay or antigen detection or electron microscopy) or 2. Acute gastroenteritis: diarrhoea or vomiting or both in a 24-h period without laboratory confirmation. |
Pneumococcal pneumonia (PnPn) | 1. Non-bacteraemic PnPn: clinical symptoms consistent with pneumonia, with a positive pneumococcal urinary antigen test (UAT) but a negative blood culture, or 2. All-cause pneumonia: clinical symptoms consistent with pneumonia, with or without x-ray confirmation, without bacteriologic confirmation |
Respiratory Syncytial Virus (RSV) | 1. Community based Acute Infection (ARI caused by RSV): sudden onset of at least one of the following symptoms: shortness of breath; cough; sore throat and coryza and a laboratory confirmation with RSV, or 2. Hospital-based Extended Severe Acute RSV Infection (SARI caused by RSV): abovementioned symptoms with onset within the last ten days, requiring hospitalisation and a laboratory confirmation with RSV. This could include severe lower respiratory tract infections, like pneumonia. |
Staphylococcus aureus (S. aureus) | Invasive S. aureus infection: clinical symptoms consistent with bacteraemia or sepsis, and isolation of S. aureus from the blood or other sterile site (synovial fluid, cerebrospinal fluid, pleural fluid, bronchoalveolar lavage, or from a sterile taken deep-seated abscess). |
Literature reviews
Results
Extra-intestinal pathogenic Escherichia coli
Survey
Indicator | ExPEC | NoV | PnPn | RSV | S.aureus |
---|---|---|---|---|---|
Summary BoD | |||||
DALY | not available | BE, NL, DK | NL | BE, DK | BE |
QALY | not available | not available | BE, NL | not available | not available |
Disability/utility | |||||
utility weights | not available | not available | NL | not available | not available |
disability weights | not available | not available | not available | not available | not available |
Morbidity | |||||
incidence/prevalence | HU, DK, IT, NO, NL | BE, DK, ES, HU, IT, NL | BE, ES, HU, IT NL, NO | BE, NL, ES, DK, IT | BE, HU, NL, DK, IT |
serotype data | NA | NA | ES, IT | NA | NA |
attributable fraction | NA | NA | BE, NL | NA | NA |
sequelae | NL | not available | not available | DK | NL, ES, DK |
disease duration | DK, NO | ES, NL | not available | BE, ES, DK | ES |
hospitalization need | HU, DK, IT, NO | BE, ES, HU, NL | BE, HU, NL | BE, NL, ES, DK | BE, HU, ES |
hospitalization duration | HU, DK, IT, NO | BE, ES, HU, NL | BE, NL | BE, NL, ES, DK | BE, HU, ES |
stratification age/RF | HU, IT, NL, NO | DK, HU | BE, ES, HU, IT, NL, NO | BE, NL, ES, DK | BE, HU, ES, NL, IT |
completeness assessment | HU | BE, NL | BE, NL | NL | HU, ES, DK |
Mortality | |||||
mortality | NO, IT | BE, DK, ES, HU | BE, ES, HU, IT, NL | NL, BE, ES, DK | ES |
serotype data | NA | NA | NA | NA | DK |
case-fatality rate | not available | not available | BE, HU | BE, ES, DK | DK |
stratification age/RF | NO | HU | BE, ES, HU, IT, NL | BE, ES | |
Antimicrobial resistance | DK, HU, IT, NL, NO | NA | NA | NA | BE, HU, NL, NO, ES, DK, IT |
Other pathogen-associated data | DK, HU, NL, NO | NA | NA | NA | BE, HU, DK |
Patient registry | NA | NA | NA | NL, ES | NA |
Literature review
Indicator | ExPEC | NoV | PnPn | RSV | S.aureus | |||||
---|---|---|---|---|---|---|---|---|---|---|
n | Countries | n | Countries | n | Countries | n | Countries | n | Countries | |
Summary BoD data | 1 | EU | 3 | NL, UK | 2 | NL | 1 | world | 0 | |
Disability/utility | 0 | 2 | NL | 2 | CH, FR | 1 | world | 0 | ||
Morbidity | ||||||||||
incidence/prevalence | 33 | AT, CH, DE, EU, DK, ES, FI, FR, IT, NO, SE, UK | 24 | CH, DE, ES, FR, IT, NL, SE, UK | 17 | DE, ES, FI, FR, IT, PO, NL, SE | 36 | BE, CH, DE, EU, ES, FR, GR, HU, NL, PO, SE, UK, world | 51 | BA, CH, DE, DK, ES, EN, EU, FI, FR, GE, GR, IE, IS, IT, ME, MK, NL, NO, PO, RO, RS, SC, SE, TR, XK |
NSS and AFa | 14 | BE, ES, IT, NL, SE, UK | 11 | BE, CH, EU, FR, UK, world | ||||||
sequelae | 4 | AT, CH, DE, DK, FR, UK | 3 | CH, NL | NA | 2 | FR, UK | 30 | AT, DE, DK, EN, ES, FI, FR, HR, IL, NO, RO, SC, SE | |
disease duration | 0 | 8 | DE, ES, FR, IT, NL, UK | 4 | BE, FR, NL, UK | 1 | world | 3 | DK, IL, SC | |
hospitalization need | 0 | 14 | CH, DE, FR, IT, NL, SE, UK | 2 | BE, FR | 15 | CH, ES, EU, FR, SE, UK, world | 11 | AT, DE, DK, HR, IS, IT, NO, SE | |
hospitalization duration | 15 | AT, DE, DK, EU, SE, UK | 4 | DE, NL, SE | 13 | ES, FR, IT, NL, UK | 7 | CH, ES, EU, FR | 27 | AT, BE, CH, DE, DK, ES, FI, FR, GR, HR, IE, NO, RO, SC, SE, TR |
Age stratification | 19 | CH, DK, DE, EU, FI, FR, IT, NO, SE, UK | 23 | CH, DE, ES, FR, IT, NL, SE, UK | 25 | BE, ES, FI, FR, IT, NL, PO, SE | 27 | BE, CH, DE, ES, EU, FR, GR, HU, NL, PO, SE, UK, world | 41 | CH, DE, DK, EN, ES, EU, FI, IE, IS, IT, NO, SC, SE |
Mortality | ||||||||||
pathogen-specific mortality | 24 | AT, DE, DK, ES, EU, FI, FR, NO, SE, UK | 10 | DE, NL, SE, UK | 75 | AT, BE, CH, DE, DK, EN, ES, FI, FR, HR, IE, IL, IS, NO, SC, SE, TR | ||||
case-fatality rate | 5 | EU, FI, NO, UK | 2 | DE, NL | 13 | DE, ES, FR, IT, NL, SE, UK | 12 | CH, ES, EU, FR, NL, SE, UK, world | 10 | DK, FI, FR, IL, NO, TR |
Antimicrobial resistance | 26 | DE, DK, ES, EU, FI, FR, IT, UK | NA | 1 | PT | NA | 63 | AT, BA, BE, CH, DE, DK, EN, ES, EU, FI, FR, GE,GR,IE, IL, IS, IT, ME, MK, NL, NO, PO, PT, RO, RS, SC, SE,TR, XK |